Long-Acting Beta Agonist Safety Issues Will Be Discussed By Advisory Committee

"Implications of recently available data" will be the subject of a July 13 meeting. The committee will also meet July 14 to discuss the continued need for essential use designations for asthma and chronic obstructive pulmonary disease therapies.